{
  "Variants Include": [
    {
      "Gene": "SNCA",
      "variants": [
        {
          "HGVS": "NM_000340.3:c.158C>T (p.A53T)",
          "cDNA Change": {
            "transcript": "NM_000340.3",
            "ref": "C",
            "alt": "T",
            "position": "158"
          },
          "Protein Change": {
            "ref": "A",
            "alt": "T",
            "position": "53"
          },
          "Description in input context": "A53T mutation in alpha-synuclein (SNCA) associated with familial Parkinson's disease"
        }
      ]
    }
  ],
  "Described Disease": {
    "Described Disease": "Parkinson's disease",
    "MONDO": "MONDO:0005172"
  },
  "Experiment Method": [
    {
      "Assay Method": "Immunohistochemistry",
      "Material used": {
        "Material Source": "Human brain tissue",
        "Material Name": "Patient-derived brain samples with A53T mutation",
        "Description": "Brain tissues from patients with the A53T mutation in SNCA were analyzed for alpha-synuclein and tau pathology."
      },
      "Readout type": "Qualitative",
      "Readout description": [
        {
          "Variant": "NM_000340.3:c.158C>T (p.A53T)",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Increased aggregation of alpha-synuclein and tau",
          "Result Description": "Immunohistochemical staining revealed abnormal accumulation of phosphorylated alpha-synuclein and tau in brain regions affected by Parkinson's disease."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "N.D.",
        "Description": "Not explicitly mentioned in the abstract."
      },
      "Technical replicates": {
        "Technical replicates": "N.D.",
        "Description": "Not explicitly mentioned in the abstract."
      },
      "Basic positive control": {
        "Basic positive control": "N.D.",
        "Description": "Not explicitly mentioned in the abstract."
      },
      "Basic negative control": {
        "Basic negative control": "N.D.",
        "Description": "Not explicitly mentioned in the abstract."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "N.D.",
        "Counts": "0"
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D.",
        "Counts": "0"
      },
      "Statistical analysis method": {
        "Statistical analysis method": "N.D."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "Normal staining patterns with no significant aggregation",
        "Source": "Custom"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Presence of phosphorylated alpha-synuclein and tau inclusions",
        "Source": "Custom"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    },
    {
      "Assay Method": "Biochemical analysis",
      "Material used": {
        "Material Source": "Brain extracts",
        "Material Name": "Brain tissue homogenates from A53T mutation carriers",
        "Description": "Biochemical assays were performed to quantify nitrated alpha-synuclein and tau levels in brain extracts."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "NM_000340.3:c.158C>T (p.A53T)",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Increased nitration of alpha-synuclein",
          "Result Description": "Biochemical analysis demonstrated elevated levels of nitrated alpha-synuclein in brain extracts from A53T mutation carriers."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "N.D.",
        "Description": "Not explicitly mentioned in the abstract."
      },
      "Technical replicates": {
        "Technical replicates": "N.D.",
        "Description": "Not explicitly mentioned in the abstract."
      },
      "Basic positive control": {
        "Basic positive control": "N.D.",
        "Description": "Not explicitly mentioned in the abstract."
      },
      "Basic negative control": {
        "Basic negative control": "N.D.",
        "Description": "Not explicitly mentioned in the abstract."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "N.D.",
        "Counts": "0"
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D.",
        "Counts": "0"
      },
      "Statistical analysis method": {
        "Statistical analysis method": "N.D."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "Normal nitrated alpha-synuclein levels",
        "Source": "Custom"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Elevated nitrated alpha-synuclein levels",
        "Source": "Custom"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    },
    {
      "Assay Method": "Ultrastructural analysis (Electron microscopy)",
      "Material used": {
        "Material Source": "Brain tissue",
        "Material Name": "Ultra-thin sections of brain tissue from A53T mutation carriers",
        "Description": "Electron microscopy was used to visualize ultrastructural changes in alpha-synuclein and tau aggregates."
      },
      "Readout type": "Qualitative",
      "Readout description": [
        {
          "Variant": "NM_000340.3:c.158C>T (p.A53T)",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Formation of filamentous inclusions",
          "Result Description": "Ultrastructural analysis revealed filamentous inclusions composed of alpha-synuclein and tau in brain regions affected by the A53T mutation."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "N.D.",
        "Description": "Not explicitly mentioned in the abstract."
      },
      "Technical replicates": {
        "Technical replicates": "N.D.",
        "Description": "Not explicitly mentioned in the abstract."
      },
      "Basic positive control": {
        "Basic positive control": "N.D.",
        "Description": "Not explicitly mentioned in the abstract."
      },
      "Basic negative control": {
        "Basic negative control": "N.D.",
        "Description": "Not explicitly mentioned in the abstract."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "N.D.",
        "Counts": "0"
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D.",
        "Counts": "0"
      },
      "Statistical analysis method": {
        "Statistical analysis method": "N.D."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "Absence of filamentous inclusions",
        "Source": "Custom"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Presence of filamentous inclusions",
        "Source": "Custom"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    },
    {
      "Assay Method": "In vitro fibrillization assays",
      "Material used": {
        "Material Source": "Recombinant proteins",
        "Material Name": "Recombinant alpha-synuclein and tau proteins with A53T mutation",
        "Description": "In vitro experiments were conducted to study the effects of the A53T mutation on alpha-synuclein and tau fibrillization."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "NM_000340.3:c.158C>T (p.A53T)",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Accelerated fibrillization of alpha-synuclein and tau",
          "Result Description": "In vitro fibrillization assays demonstrated that the A53T mutation in alpha-synuclein significantly accelerated the formation of fibrils, which were further stabilized by tau."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "N.D.",
        "Description": "Not explicitly mentioned in the abstract."
      },
      "Technical replicates": {
        "Technical replicates": "N.D.",
        "Description": "Not explicitly mentioned in the abstract."
      },
      "Basic positive control": {
        "Basic positive control": "N.D.",
        "Description": "Not explicitly mentioned in the abstract."
      },
      "Basic negative control": {
        "Basic negative control": "N.D.",
        "Description": "Not explicitly mentioned in the abstract."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "N.D.",
        "Counts": "0"
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D.",
        "Counts": "0"
      },
      "Statistical analysis method": {
        "Statistical analysis method": "N.D."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "Normal fibrillization rates",
        "Source": "Custom"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Accelerated fibrillization rates",
        "Source": "Custom"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    }
  ]
}